Delius Pharma Clocks 672.50% Q1 Growth, Eyes ₹350 Crores in FY25 Competitors Left Counting Dust

Mumbai, September, 19— Delius Pharmaceuticals Pvt Ltd, India’s fastest-rising bulk drug makers in the generics formulations space, has reported a 672.50% year-on-year revenue jump in Q1 FY 25-26, The sharp surge was driven by robust sales in its cephalosporin and ampicillin beta-lactam branded generics portfolio, expansion in branded generics, and the start of large-scale imports from China.

 

The company’s profitability has also improved on the back of stronger margins in its core antibiotics range. Notably, this quarter saw Delius make a strategic talent grab from key competitors. Industry veteran Sanjeev (ex-Apex Healthcare), credited with building the Zincovit brand, has joined to lead the prescription-based doctor engagement model. Jay (ex-Ranbaxy, Sanofi, GSK, Dr. Reddy’s, Airtel) will handle pan-India doctor relations, while Ajeet (ex-Glenmark, Ipca, Indoco) brings operational depth to the leadership team.

 

Strengthening its supply chain, Delius signed a landmark deal with Chinese API giant Apeloa for 100 tons of 6-APA and ester supply, securing critical raw material flow and cost efficiencies.

 

Delius Group Chairman, Digvijay Shrivastawa, stated: Our strategy is clear — capture the generics market from its very foundation. From distributors and hospitals to chemists and retail counters, we are strengthening every channel. This year, Delius will set a new benchmark in the critical antibiotics segment.

 

With exports set to accelerate, the company is guiding for ₹280 crore in generics formulations turnover this year and is pushing towards ₹350 crore by FY 25-26 end. Backed by a ₹70 crore bank-supported investment in new beta and non-beta manufacturing plant, Delius is gearing up to scale both capacity and R&D, positioning itself as a serious contender in India’s pharma growth story.